<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39324900</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-7048</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Current opinion in hematology</Title><ISOAbbreviation>Curr Opin Hematol</ISOAbbreviation></Journal><ArticleTitle>Viral infection after hematopoietic stem cell transplantation.</ArticleTitle><Pagination><StartPage>270</StartPage><EndPage>274</EndPage><MedlinePgn>270-274</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MOH.0000000000000833</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Viral infections are important complications after allogeneic hematopoietic stem cell transplantation. New infections develop such as SARS-CoV-2 with the potential for severe consequences. In this review, newly published information regarding management of viral infections is discussed.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Letermovir and maribavir are antiviral agents that have positively impacted the management of cytomegalovirus infections. These should today be included in treatment algorithms. The first antiviral cellular therapy for anti-CD20 refractory EBV-associated lymphoproliferative disease is now licensed and available. Vaccination as well as introduction of antiviral agents, mAbs and possibly the development of different viral strains have reduced mortality in COVID-19 in this patient population. Well designed studies have shown the improved immunogenicity of high-dose influenza vaccines. There is still an unmet medical need for patients infected with human metapneumovirus and parainfluenza viruses.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Although improvements in patient management for several important posttransplantation viral infections have been reported, an unmet medical need still exists for other viruses occurring in this high-risk population.</AbstractText><CopyrightInformation>Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ljungman</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Department of Cellular Therapy and allogeneic Stem Cell Transplantation, Karolinska University Hospital, Karolinska Comprehensive Cancer Center, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Hematol</MedlineTA><NlmUniqueID>9430802</NlmUniqueID><ISSNLinking>1065-6251</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39324900</ArticleId><ArticleId IdType="doi">10.1097/MOH.0000000000000833</ArticleId><ArticleId IdType="pii">00062752-202411000-00004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Portillo V, Masouridi-Levrat S, Royston L, et al. Revisiting Cytomegalovirus Serology in Allogeneic Hematopoietic Cell Transplant Recipients. Clin Infect Dis 2024; 78:423–429.</Citation></Reference><Reference><Citation>Marty FM, Ljungman P, Chemaly RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med 2017; 377:2433–2444.</Citation></Reference><Reference><Citation>Vyas A, Raval AD, Kamat S, et al. Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies. Open Forum Infect Dis 2023; 10:ofac687.</Citation></Reference><Reference><Citation>Russo D, Schmitt M, Pilorge S, et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol 2024; 11:e127–e135.</Citation></Reference><Reference><Citation>Politikos I, Lau C, Devlin SM, et al. Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults. Blood Adv 2022; 6:6291–6300.</Citation></Reference><Reference><Citation>Lin A, Flynn J, DeRespiris L, et al. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Transplant Cell Ther 2021; 27:85 e1-e6.</Citation></Reference><Reference><Citation>Lin A, Brown S, Chinapen S, Lee YJ, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant. Blood Adv 2023; 7:7153–7160.</Citation></Reference><Reference><Citation>Goldsmith SR, Abid MB, Auletta JJ, et al. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood 2021; 137:3291–3305.</Citation></Reference><Reference><Citation>Sadowska-Klasa A, Ozkok S, Xie H, et al. Late Cytomegalovirus Disease after Hematopoietic Cell Transplantation: Significance of Novel Transplantation Techniques. Blood Adv 2024; 9:3639–3651.</Citation></Reference><Reference><Citation>Avery RK, Alain S, Alexander BD, et al. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clin Infect Dis 2022; 75:690–701.</Citation></Reference><Reference><Citation>Chou S, Alain S, Cervera C, et al. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. J Infect Dis 2024; 229:413–421.</Citation></Reference><Reference><Citation>Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. N Engl J Med 2019; 381:1136–1147.</Citation></Reference><Reference><Citation>Papanicolaou GA, Avery RK, Cordonnier C, et al. Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir. Clin Infect Dis 2024; 78:562–572.</Citation></Reference><Reference><Citation>Mahadeo KM, Baiocchi R, Beitinjaneh A, Chaganti S, et al. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive posttransplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. The Lancet Oncology 2024; 25:376–387.</Citation></Reference><Reference><Citation>Ljungman P, de la Camara R, Mikulska M, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2021; 35:2885–2894.</Citation></Reference><Reference><Citation>Pagano L, Salmanton-Garcia J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol 2021; 14:168.</Citation></Reference><Reference><Citation>Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol 2021; 8:e185–e193.</Citation></Reference><Reference><Citation>Salmanton-Garcia J, Marchesi F, Farina F, et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine 2024; 71:102553.</Citation></Reference><Reference><Citation>Ljungman P, Tridello G, Piñana JL, et al. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. Front Immunol 2023; 14:1125824.</Citation></Reference><Reference><Citation>Nimgaonkar I, Yoke LH, Roychoudhury P, et al. Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T Cell Therapy Recipients with Pre-Cellular Therapy SARS-CoV-2 Infection. Clin Infect Dis 2024; 19:86–91.</Citation></Reference><Reference><Citation>Bergman P, Blennow O, Hansson L, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine 2021; 74:103705.</Citation></Reference><Reference><Citation>Matkowska-Kocjan A, Owoc-Lempach J, Chruszcz J, et al. The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation. Vaccines (Basel) 2021; 9:1209.</Citation></Reference><Reference><Citation>Hill JA, Martens MJ, Young JH, et al. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study. Clin Infect Dis 2024; doi: 10.1093/cid/ciae291. [Online ahead of print].</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciae291.</ArticleId></ArticleIdList></Reference><Reference><Citation>Piñana JL, Perez A, Montoro J, et al. Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. Clin Infect Dis 2019; 68:1894–1903.</Citation></Reference><Reference><Citation>Kumar D, Ferreira VH, Blumberg E, et al. A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients. Clin Infect Dis 2018; 67:1322–1329.</Citation></Reference><Reference><Citation>Cordonnier C, Einarsdottir S, Cesaro S, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet infectious diseases 2019; 19:e200–e212.</Citation></Reference><Reference><Citation>Kamboj M, Bohlke K, Baptiste DM, et al. Vaccination of Adults With Cancer: ASCO Guideline. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2024; 42:1699–1721.</Citation></Reference><Reference><Citation>Schuster JE, Hamdan L, Dulek DE, et al. Influenza Vaccine in Pediatric Recipients of Hematopoietic-Cell Transplants. N Engl J Med 2023; 388:374–376.</Citation></Reference><Reference><Citation>Schuster JE, Hamdan L, Dulek DE, et al. The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial. Clin Infect Dis 2024; 78:217–226.</Citation></Reference><Reference><Citation>Piñana JL, Tridello G, Xhaard A, et al. Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation. J Infect Dis 2024; 229:83–94.</Citation></Reference><Reference><Citation>Seo S, Xie H, Leisenring WM, et al. Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2019; 25:163–171.</Citation></Reference><Reference><Citation>Seo S, Xie H, Campbell AP, et al. Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome. Clin Infect Dis 2014; 58:1357–1368.</Citation></Reference><Reference><Citation>Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98:573–578.</Citation></Reference><Reference><Citation>Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood 2012; 119:2738–2745. quiz 969.</Citation></Reference><Reference><Citation>Sparrelid E, Ljungman P, Ekelof-Andstrom E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplantation 1997; 19:905–908.</Citation></Reference><Reference><Citation>Perez A, Montoro J, Chorao P, et al. Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy. Infection 2024; doi: 10.1007/s15010-024-02213-0. [Online ahead of print].</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-024-02213-0.</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>